Table 1.
Patient characteristics
| No. of patients (%) | |
|---|---|
| Age (years) | |
| Median | 50 |
| Range | 15–84 |
| Gender | |
| Male | 51 (51.5) |
| Female | 48 (48.5) |
| Any chronic comorbidity | |
| No | 72 (72.7) |
| Yes | 27 (27.3) |
| Tumor site | |
| Lower extremity | 73 (73.7) |
| Upper extremity | 26 (26.3) |
| Tumor size (cm) | |
| ≤ 5 | 34 (34.3) |
| > 5 | 61 (61.6) |
| Unknowna | 4 (4.0) |
| Tumor depth | |
| Superficial | 30 (30.3) |
| Deep | 69 (69.7) |
| FNCLCC grade | |
| 1 | 17 (17.2) |
| 2 | 50 (50.5) |
| 3 | 32 (32.3) |
| Histological subtype | |
| MFH | 35 (35.4) |
| Myxoid liposarcoma | 26 (26.3) |
| Synovial sarcoma | 10 (10.1) |
| Dedifferentiated liposarcoma | 8 (8.1) |
| Myxofibrosarcoma | 5 (5.1) |
| Fibrosarcoma | 5 (5.1) |
| MPNST | 5 (5.1) |
| Ewing sarcoma/ PNET | 5 (5.1) |
| Resection margin | |
| Negative | 77 (77.8) |
| Close (≤2 mm) | 9 (9.1) |
| Positive | 10 (10.1) |
| Unknowna | 3 (3.0) |
| Treatment modality | |
| Surgery + RT | 58 (58.6) |
| Surgery + RT + CXT | 41 (41.4) |
| RT dose (Gy) | |
| Median | 60 |
| Range | 46–66 |
Abbreviations: FNCLCC Fédération Nationale des Centres de Lutte Contre le Cancer, MFH malignant fibrous histiocytoma, MPNST malignant peripheral nerve sheath tumor, PNET primitive neuroectodermal tumor, RT radiotherapy, CXT chemotherapy
aIt was not possible to evaluate in patients who underwent excision at an outside institution